Free Trial
NASDAQ:XLO

Xilio Therapeutics Q1 2024 Earnings Report

Xilio Therapeutics logo
$0.67 -0.03 (-3.85%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$0.66 0.00 (-0.23%)
As of 05/7/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A

Xilio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xilio Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Xilio Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 16, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xilio Therapeutics Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year
Xilio Therapeutics files $250M mixed securities shelf
See More Xilio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email.

About Xilio Therapeutics

Xilio Therapeutics (NASDAQ:XLO), a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

View Xilio Therapeutics Profile

More Earnings Resources from MarketBeat